AtriCure (ATRC) has drawn investor attention after a period of mixed share performance, with a loss of 9.18% over the past month but a 16.83% gain in the past 3 months.

At a share price of $36.80, AtriCure’s recent 7 day and 1 month share price returns of 2.57% and 9.18% declines contrast with a 16.83% gain over 90 days. The 1 year, 3 year and 5 year total shareholder returns of 10.96%, 13.92% and 41.49% declines indicate that momentum has only recently turned more supportive after a longer period of weaker performance.

If AtriCure’s recent moves have you reassessing healthcare names, it could be a good moment to broaden your watchlist with healthcare stocks.

With AtriCure shares around $36.80, a value score of 3 and an analyst price target of $52.78, the big question is whether the current discount signals an undervalued opportunity or whether markets already reflect future growth.

Most Popular Narrative: 30.3% Undervalued

With AtriCure last closing at $36.80 against a narrative fair value of $52.78, the current gap sets up a clear valuation debate for investors.

The successful completion of enrollment in the LeAAPS clinical trial, as well as early activation of the BoxX-NoAF study, are set to substantially increase AtriCure's total addressable market if positive outcomes lead to expanded indications for stroke prevention and preventative cardiac surgery in underserved populations, which will support future revenue and earnings growth.

Curious what kind of revenue trajectory, margin uplift and future earnings multiple need to line up to support that $52.78 figure at a 7.73% discount rate? The most followed narrative lays out a tight set of assumptions around growth, profitability and share count that all have to work together to justify that valuation path.

Result: Fair Value of $52.78 (UNDERVALUED)

However, there are still important swing factors, including pressure from pulsed field ablation competitors and the possibility that key trials or new products fail to deliver the expected uptake.

Another View: Multiples Paint A Tougher Picture

While the analyst narrative points to a fair value of $52.78, the current P/S ratio of 3.5x complicates the story. It sits above the US Medical Equipment industry at 2.9x, below the peer average of 5.9x, and close to a fair ratio of 3.6x, so how much room is really left?

Build Your Own AtriCure Narrative

If you do not fully agree with these views or prefer to lean on your own research, you can quickly build a custom view of AtriCure using Do it your way.

A great starting point for your AtriCure research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If AtriCure has sparked your interest, do not stop here. Broaden your opportunity set with a few focused stock ideas that many investors overlook.

• Spot potential value opportunities early by zeroing in on these 861 undervalued stocks based on cash flows. These may be pricing in more caution than their cash flows suggest.
• Ride powerful tech trends by scanning these 30 AI penny stocks. These tie artificial intelligence themes to real business models and financials.
• Target higher portfolio income by focusing on these 11 dividend stocks with yields > 3%. These combine meaningful yields with listed cash flow support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.